AAPL342.46-1.01 (-0.29%) ▼|ABBV283.23-2.19 (-0.77%) ▼|ABT103.77-1.12 (-1.07%) ▼|ACN231.93+2.25 (+0.98%) ▲|ADBE244.88-0.33 (-0.13%) ▼|AMAT423.98+14.69 (+3.59%) ▲|AMD548.48+19.73 (+3.73%) ▲|AMGN427.01-5.49 (-1.27%) ▼|AMT182.77-2.50 (-1.35%) ▼|AMZN262.97+12.97 (+5.19%) ▲|AVGO339.14+10.39 (+3.16%) ▲|AXP313.39-0.21 (-0.07%) ▼|BA191.44+1.23 (+0.64%) ▲|BAC50.53-0.71 (-1.38%) ▼|BKNG161.04-2.41 (-1.47%) ▼|BLK1,128.55-5.83 (-0.51%) ▼|BMY58.66-1.10 (-1.83%) ▼|BNY143.11-0.20 (-0.14%) ▼|BRK-B530.62-1.41 (-0.26%) ▼|C122.91-1.35 (-1.09%) ▼|CAT730.66-0.10 (-0.01%) ▼|CL93.04-1.07 (-1.14%) ▼|CMCSA21.72-0.19 (-0.84%) ▼|COF199.66-2.08 (-1.03%) ▼|COP144.69-1.82 (-1.24%) ▼|COST990.00+0.89 (+0.09%) ▲|CRM239.54-1.16 (-0.48%) ▼|CSCO107.35-0.04 (-0.04%) ▼|CVS91.22-1.14 (-1.23%) ▼|CVX223.64-1.35 (-0.60%) ▼|DE629.94-11.92 (-1.86%) ▼|DHR225.22-3.82 (-1.67%) ▼|DIS109.71-0.89 (-0.80%) ▼|DUK119.56-1.92 (-1.58%) ▼|EMR161.73+0.26 (+0.16%) ▲|FDX292.88-0.67 (-0.23%) ▼|GD341.62-2.61 (-0.76%) ▼|GE312.35-1.48 (-0.47%) ▼|GEV921.84+0.64 (+0.07%) ▲|GILD154.68-1.51 (-0.97%) ▼|GM82.42-1.54 (-1.83%) ▼|GOOG341.25+4.34 (+1.29%) ▲|GOOGL345.42+4.83 (+1.42%) ▲|GS881.36+0.10 (+0.01%) ▲|HD309.40-0.23 (-0.07%) ▼|HON211.09-0.33 (-0.15%) ▼|IBM236.12+3.98 (+1.71%) ▲|INTC94.58+4.73 (+5.26%) ▲|INTU321.82-3.33 (-1.02%) ▼|ISRG432.22+5.52 (+1.29%) ▲|JNJ252.70-2.86 (-1.12%) ▼|JPM335.60-4.12 (-1.21%) ▼|KO93.60-0.30 (-0.32%) ▼|LIN501.56+3.13 (+0.63%) ▲|LLY1,248.36-8.67 (-0.69%) ▼|LMT549.50-2.59 (-0.47%) ▼|LOW195.48-1.91 (-0.97%) ▼|LRCX278.52+14.58 (+5.52%) ▲|MA613.06-4.36 (-0.71%) ▼|MCD242.34-0.64 (-0.26%) ▼|MDLZ63.57-0.34 (-0.53%) ▼|MDT92.88-1.88 (-1.98%) ▼|META703.34-5.99 (-0.84%) ▼|MMM163.79-0.96 (-0.58%) ▼|MO74.23-0.88 (-1.17%) ▼|MRK144.60-1.35 (-0.93%) ▼|MS179.96-0.61 (-0.34%) ▼|MSFT534.15+5.10 (+0.96%) ▲|MU919.77+40.93 (+4.66%) ▲|NEE78.56-1.24 (-1.55%) ▼|NFLX69.68-0.86 (-1.21%) ▼|NKE36.84-0.30 (-0.79%) ▼|NOW143.89+1.92 (+1.35%) ▲|NVDA219.54+5.41 (+2.53%) ▲|ORCL130.69+2.46 (+1.91%) ▲|PEP132.38+0.89 (+0.68%) ▲|PFE29.30-0.29 (-0.96%) ▼|PG157.22-2.13 (-1.34%) ▼|PLTR196.03+10.00 (+5.38%) ▲|PM201.78-3.42 (-1.67%) ▼|QCOM173.83+1.72 (+1.00%) ▲|RTX191.84-2.09 (-1.08%) ▼|SBUX97.95+0.43 (+0.44%) ▲|SCHW90.19-1.77 (-1.92%) ▼|SO89.67-1.52 (-1.66%) ▼|SPG203.50-1.94 (-0.94%) ▼|T23.11-0.34 (-1.43%) ▼|TMO677.03-12.97 (-1.88%) ▼|TMUS157.62-1.48 (-0.93%) ▼|TSLA367.63+12.91 (+3.64%) ▲|TXN274.55-1.93 (-0.70%) ▼|UBER70.39+0.04 (+0.05%) ▲|UNH401.77+0.34 (+0.08%) ▲|UNP286.76-2.28 (-0.79%) ▼|UPS97.32-0.17 (-0.17%) ▼|USB58.21-0.53 (-0.89%) ▼|V401.95-0.67 (-0.17%) ▼|VZ44.11-0.68 (-1.52%) ▼|WFC82.17-1.71 (-2.03%) ▼|WMT118.35-0.47 (-0.39%) ▼|XOM177.58-1.40 (-0.78%) ▼|AAPL342.46-1.01 (-0.29%) ▼|ABBV283.23-2.19 (-0.77%) ▼|ABT103.77-1.12 (-1.07%) ▼|ACN231.93+2.25 (+0.98%) ▲|ADBE244.88-0.33 (-0.13%) ▼|AMAT423.98+14.69 (+3.59%) ▲|AMD548.48+19.73 (+3.73%) ▲|AMGN427.01-5.49 (-1.27%) ▼|AMT182.77-2.50 (-1.35%) ▼|AMZN262.97+12.97 (+5.19%) ▲|AVGO339.14+10.39 (+3.16%) ▲|AXP313.39-0.21 (-0.07%) ▼|BA191.44+1.23 (+0.64%) ▲|BAC50.53-0.71 (-1.38%) ▼|BKNG161.04-2.41 (-1.47%) ▼|BLK1,128.55-5.83 (-0.51%) ▼|BMY58.66-1.10 (-1.83%) ▼|BNY143.11-0.20 (-0.14%) ▼|BRK-B530.62-1.41 (-0.26%) ▼|C122.91-1.35 (-1.09%) ▼|CAT730.66-0.10 (-0.01%) ▼|CL93.04-1.07 (-1.14%) ▼|CMCSA21.72-0.19 (-0.84%) ▼|COF199.66-2.08 (-1.03%) ▼|COP144.69-1.82 (-1.24%) ▼|COST990.00+0.89 (+0.09%) ▲|CRM239.54-1.16 (-0.48%) ▼|CSCO107.35-0.04 (-0.04%) ▼|CVS91.22-1.14 (-1.23%) ▼|CVX223.64-1.35 (-0.60%) ▼|DE629.94-11.92 (-1.86%) ▼|DHR225.22-3.82 (-1.67%) ▼|DIS109.71-0.89 (-0.80%) ▼|DUK119.56-1.92 (-1.58%) ▼|EMR161.73+0.26 (+0.16%) ▲|FDX292.88-0.67 (-0.23%) ▼|GD341.62-2.61 (-0.76%) ▼|GE312.35-1.48 (-0.47%) ▼|GEV921.84+0.64 (+0.07%) ▲|GILD154.68-1.51 (-0.97%) ▼|GM82.42-1.54 (-1.83%) ▼|GOOG341.25+4.34 (+1.29%) ▲|GOOGL345.42+4.83 (+1.42%) ▲|GS881.36+0.10 (+0.01%) ▲|HD309.40-0.23 (-0.07%) ▼|HON211.09-0.33 (-0.15%) ▼|IBM236.12+3.98 (+1.71%) ▲|INTC94.58+4.73 (+5.26%) ▲|INTU321.82-3.33 (-1.02%) ▼|ISRG432.22+5.52 (+1.29%) ▲|JNJ252.70-2.86 (-1.12%) ▼|JPM335.60-4.12 (-1.21%) ▼|KO93.60-0.30 (-0.32%) ▼|LIN501.56+3.13 (+0.63%) ▲|LLY1,248.36-8.67 (-0.69%) ▼|LMT549.50-2.59 (-0.47%) ▼|LOW195.48-1.91 (-0.97%) ▼|LRCX278.52+14.58 (+5.52%) ▲|MA613.06-4.36 (-0.71%) ▼|MCD242.34-0.64 (-0.26%) ▼|MDLZ63.57-0.34 (-0.53%) ▼|MDT92.88-1.88 (-1.98%) ▼|META703.34-5.99 (-0.84%) ▼|MMM163.79-0.96 (-0.58%) ▼|MO74.23-0.88 (-1.17%) ▼|MRK144.60-1.35 (-0.93%) ▼|MS179.96-0.61 (-0.34%) ▼|MSFT534.15+5.10 (+0.96%) ▲|MU919.77+40.93 (+4.66%) ▲|NEE78.56-1.24 (-1.55%) ▼|NFLX69.68-0.86 (-1.21%) ▼|NKE36.84-0.30 (-0.79%) ▼|NOW143.89+1.92 (+1.35%) ▲|NVDA219.54+5.41 (+2.53%) ▲|ORCL130.69+2.46 (+1.91%) ▲|PEP132.38+0.89 (+0.68%) ▲|PFE29.30-0.29 (-0.96%) ▼|PG157.22-2.13 (-1.34%) ▼|PLTR196.03+10.00 (+5.38%) ▲|PM201.78-3.42 (-1.67%) ▼|QCOM173.83+1.72 (+1.00%) ▲|RTX191.84-2.09 (-1.08%) ▼|SBUX97.95+0.43 (+0.44%) ▲|SCHW90.19-1.77 (-1.92%) ▼|SO89.67-1.52 (-1.66%) ▼|SPG203.50-1.94 (-0.94%) ▼|T23.11-0.34 (-1.43%) ▼|TMO677.03-12.97 (-1.88%) ▼|TMUS157.62-1.48 (-0.93%) ▼|TSLA367.63+12.91 (+3.64%) ▲|TXN274.55-1.93 (-0.70%) ▼|UBER70.39+0.04 (+0.05%) ▲|UNH401.77+0.34 (+0.08%) ▲|UNP286.76-2.28 (-0.79%) ▼|UPS97.32-0.17 (-0.17%) ▼|USB58.21-0.53 (-0.89%) ▼|V401.95-0.67 (-0.17%) ▼|VZ44.11-0.68 (-1.52%) ▼|WFC82.17-1.71 (-2.03%) ▼|WMT118.35-0.47 (-0.39%) ▼|XOM177.58-1.40 (-0.78%) ▼|
15.1 C
New York
Monday, October 19, 2026

Tag: hydration

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

PureHealth Research Utilizes Bioavailable Cranberry and Astragalus in Premium Natural Supplements for Kidney Health

MANASSAS, Va., June 13, 2026 /PRNewswire/ -- PureHealth Research today addressed the growing demand for proactive kidney wellness with its collection of science-backed renal...

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

OZOP Energy Solutions, Inc. Highlights Southern California Market Entry Through Tenace Consulting as Regional Distribution Partnership

WARWICK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Ozop Energy Solutions, Inc. (OTC: OZSC, the “Company”) today announced Ballislife Drink Inc.’s entry into the Southern California market through Varon Corp’s U.S. subsidiary, Varon USA, supported by the appointment of Tenace Consulting (Tenace) as its regional distribution partner. Ozop and Varon Corp are currently completing customary pre-closing conditions in connection with the previously announced transaction with OZOP.

GoveeLife Launches Smart Countertop Ice Maker 2 Pro for Iced Coffee and Summer Hosting

The bullet ice maker delivers first ice in as fast as 3 minutes, up to 47 lb of daily ice production, and up to...

MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale

MONROE, N.J. and RANCHO CUCAMONGA, Calif., June 7, 2026 /PRNewswire/ -- For 12 years, MimiSilk, the at-home beauty device brand, has remained committed to a single...

MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale

MONROE, N.J. and RANCHO CUCAMONGA, Calif., June 7, 2026 /PRNewswire/ -- For 12 years, MimiSilk, the at-home beauty device brand, has remained committed to a single...

Clinical Amino Acid Profiles Anchor PureHealth Research’s New Natural Peptides Supplements

MANASSAS, Va., June 6, 2026 /PRNewswire/ -- PureHealth Research today pointed to the growing scientific interest in naturally sourced peptide nutrition for healthy aging...

AMASS Brands Group Secures First U.S. Distribution Partner for AMASS Electrolyte Mixers

Great Lakes Wine & Spirits, One of the Midwest’s Most Established Distribution Networks, to Launch AMASS Electrolyte Mixers Across Michigan

CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS

The multi-day event united global creators in Hollywood for a content creation competition experience to educate and entertain consumers on healthy skin habits.NEW YORK,...

CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS

The multi-day event united global creators in Hollywood for a content creation competition experience to educate and entertain consumers on healthy skin habits.NEW YORK,...

MISOORA Unveils Revolutionary K-Beauty Skincare Range Emphasizing Longevity Over Anti-Aging

A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut.
A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut.

SPIRIT HACKS INTO SUMMERWEEN WITH LIMITED EDITION TERRIFIER COLLECTION

From Art the Clown Pool Floats to Terrifier Totes, Spirit's Officially-Licensed Collection Has Everything You Need to Make Your Summerween a Total ScreamEGG HARBOR TOWNSHIP, N.J.,...

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHydration